MAPT and Alzheimer disease: Comparing AD groups with respective controls, a statistically significant difference in mean value was found for most AD pathologies and co-pathologies, indicating significantly higher pathology burden in the AD groups (MTL tau-PET SUVR, aHC/PHC ratio as TDP-43 proxy, CSF Aβ42/Aβ40 ratio; Fig. 2, supplementary material sTable S6).